Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidine

Ankerst, Jaro LU orcid ; Fäldt, Roger LU ; Nilsson, P. G. LU ; Flodgren, Per LU and Sjögren, H. O. LU (1984) In Cancer Immunology Immunotherapy 17(1). p.69-71
Abstract

A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no... (More)

A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Immunology Immunotherapy
volume
17
issue
1
pages
69 - 71
publisher
Springer
external identifiers
  • pmid:6587932
  • scopus:0021276520
ISSN
0340-7004
DOI
10.1007/BF00205501
language
English
LU publication?
yes
id
1b90d91a-8b19-427b-94c2-84b8044e9ebc
date added to LUP
2021-01-18 16:36:32
date last changed
2024-01-03 05:23:03
@article{1b90d91a-8b19-427b-94c2-84b8044e9ebc,
  abstract     = {{<p>A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.</p>}},
  author       = {{Ankerst, Jaro and Fäldt, Roger and Nilsson, P. G. and Flodgren, Per and Sjögren, H. O.}},
  issn         = {{0340-7004}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{69--71}},
  publisher    = {{Springer}},
  series       = {{Cancer Immunology Immunotherapy}},
  title        = {{Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidine}},
  url          = {{http://dx.doi.org/10.1007/BF00205501}},
  doi          = {{10.1007/BF00205501}},
  volume       = {{17}},
  year         = {{1984}},
}